Merck Reports Positive ENFLONSIA Data for High-Risk Children in Second RSV Season
ENFLONSIA RSV data from the Phase 3 SMART trial show positive results for infants and children under 2 years at increased risk for severe respiratory syncytial virus (RSV) disease....

